Company intelligence / Profile preview

ISU Abxis Co., Ltd.

Seongnam-si, Gyeonggi-do, South Koreaabxis.com ↗

Ownership: Public · 086890
Employees: ~62
Development stage: Phase 1

Overview

ISU Abxis has successfully developed and commercialized several biomedicines, including Abcertin for Gaucher's disease and Fabagal for Fabry's disease. They are also working on preclinical projects like ISU-203 for Alzheimer's disease.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Monoclonal antibodiesBiosimilarsEnzymes
Industry: Biotech

Drug pipeline

5 assets

Clotinab

4 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with domestic pharmaceutical companies

Beyond the preview

Go deeper on ISU Abxis Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISU Abxis Co., Ltd..

Explore the full profile